Pain is a common symptom associated with cancer and its treatment. Pain management is an important aspect of oncologic care, and unrelieved pain significantly comprises overall quality of life. These NCCN Guidelines list the principles of management and acknowledge the range of complex decisions faced in the management oncologic pain. In addition to pain assessment techniques, these guidelines provide principles of use, dosing, management of adverse effects, and safe handling procedures of pharmacologic therapies and discuss a multidisciplinary approach for the management of cancer pain.
WeinsteinSM, PortenoyR, HarringtonS. UNIPAC 3: Assessment and Treatment of Physical Pain Associated with Life-Limiting Illness. 4th edition. Glenview, Illinois: American Academy of Hospice and Palliative Medicine; 2012.
WeinsteinSMPortenoyRHarringtonS. UNIPAC 3: Assessment and Treatment of Physical Pain Associated with Life-Limiting Illness. 4th edition. Glenview, Illinois: American Academy of Hospice and Palliative Medicine; 2012.
)| false
CohenMZ, EasleyMK, EllisC. Cancer pain management and the JCAHO’s pain standards: an institutional challenge. J Pain Symptom Manage2003;25:519–527.
CohenMZEasleyMKEllisC. Cancer pain management and the JCAHO’s pain standards: an institutional challenge. J Pain Symptom Manage2003;25:519–527.
)| false
SvendsenKB, AndersenS, ArnasonS. Breakthrough pain in malignant and non-malignant diseases: a review of prevalence, characteristics and mechanisms. Eur J Pain2005;9:195–206.
SvendsenKBAndersenSArnasonS. Breakthrough pain in malignant and non-malignant diseases: a review of prevalence, characteristics and mechanisms. Eur J Pain2005;9:195–206.
)| false
StjernswardJ, ColleauSM, VentafriddaV. The World Health Organization Cancer Pain and Palliative Care Program. Past, present, and future. J Pain Symptom Manage1996;12:65–72.
StjernswardJColleauSMVentafriddaV. The World Health Organization Cancer Pain and Palliative Care Program. Past, present, and future. J Pain Symptom Manage1996;12:65–72.
)| false
SerlinRC, MendozaTR, NakamuraY. When is cancer pain mild, moderate or severe? Grading pain severity by its interference with function. Pain1995;61:277–284.
SerlinRCMendozaTRNakamuraY. When is cancer pain mild, moderate or severe? Grading pain severity by its interference with function. Pain1995;61:277–284.
)| false
SoetengaD, FrankJ, PellinoTA. Assessment of the validity and reliability of the University of Wisconsin Children’s Hospital Pain scale for Preverbal and Nonverbal Children. Pediatr Nurs1999;25:670–676.
SoetengaDFrankJPellinoTA. Assessment of the validity and reliability of the University of Wisconsin Children’s Hospital Pain scale for Preverbal and Nonverbal Children. Pediatr Nurs1999;25:670–676.
)| false
AkbikH, ButlerSF, BudmanSH. Validation and clinical application of the Screener and Opioid Assessment for Patients with Pain (SOAPP). J Pain Symptom Manage2006;32:287–293.
AkbikHButlerSFBudmanSH. Validation and clinical application of the Screener and Opioid Assessment for Patients with Pain (SOAPP). J Pain Symptom Manage2006;32:287–293.
)| false
PassikSD, KirshKL. The interface between pain and drug abuse and the evolution of strategies to optimize pain management while minimizing drug abuse. Exp Clin Psychopharmacol2008;16:400–404.
PassikSDKirshKL. The interface between pain and drug abuse and the evolution of strategies to optimize pain management while minimizing drug abuse. Exp Clin Psychopharmacol2008;16:400–404.
)| false
ChouR, FanciulloGJ, FinePG. Opioids for chronic noncancer pain: prediction and identification of aberrant drug-related behaviors: a review of the evidence for an American Pain Society and American Academy of Pain Medicine clinical practice guideline. J Pain2009;10:131–146.
ChouRFanciulloGJFinePG. Opioids for chronic noncancer pain: prediction and identification of aberrant drug-related behaviors: a review of the evidence for an American Pain Society and American Academy of Pain Medicine clinical practice guideline. J Pain2009;10:131–146.
)| false
SyrjalaKL, AbramsJR, PolissarNL. Patient training in cancer pain management using integrated print and video materials: a multisite randomized controlled trial. Pain2008;135:175–186.
SyrjalaKLAbramsJRPolissarNL. Patient training in cancer pain management using integrated print and video materials: a multisite randomized controlled trial. Pain2008;135:175–186.
)| false
American Pain Society. Principles of Analgesic Use in the Treatment of Acute Pain and Cancer Pain. 5th ed.Glenview, IL: American Pain Society; 2003.
American Pain Society. Principles of Analgesic Use in the Treatment of Acute Pain and Cancer Pain. 5th ed.Glenview, IL: American Pain Society; 2003.
)| false
MercadanteSL, BerchovichM, CasuccioA. A prospective randomized study of corticosteroids as adjuvant drugs to opioids in advanced cancer patients. Am J Hosp Palliat Care2007;24:13–19.
MercadanteSLBerchovichMCasuccioA. A prospective randomized study of corticosteroids as adjuvant drugs to opioids in advanced cancer patients. Am J Hosp Palliat Care2007;24:13–19.
)| false
MercadanteS, ArcuriE, FerreraP. Alternative treatments of breakthrough pain in patients receiving spinal analgesics for cancer pain. J Pain Symptom Manage2005;30:485–491.
MercadanteSArcuriEFerreraP. Alternative treatments of breakthrough pain in patients receiving spinal analgesics for cancer pain. J Pain Symptom Manage2005;30:485–491.
)| false
LinCC, ChouPL, WuSL. Long-term effectiveness of a patient and family pain education program on overcoming barriers to management of cancer pain. Pain2006;122:271–281.
LinCCChouPLWuSL. Long-term effectiveness of a patient and family pain education program on overcoming barriers to management of cancer pain. Pain2006;122:271–281.
)| false
ChangMC, ChangYC, ChiouJF. Overcoming patient-related barriers to cancer pain management for home care patients. A pilot study. Cancer Nurs2002;25:470–476.
ChangMCChangYCChiouJF. Overcoming patient-related barriers to cancer pain management for home care patients. A pilot study. Cancer Nurs2002;25:470–476.
)| false
KlepstadP, KaasaS, BorchgrevinkPC. Start of oral morphine to cancer patients: effective serum morphine concentrations and contribution from morphine-6-glucuronide to the analgesia produced by morphine. Eur J Clin Pharmacol2000;55:713–719.
KlepstadPKaasaSBorchgrevinkPC. Start of oral morphine to cancer patients: effective serum morphine concentrations and contribution from morphine-6-glucuronide to the analgesia produced by morphine. Eur J Clin Pharmacol2000;55:713–719.
)| false
KlepstadP, KaasaS, SkaugeM, BorchgrevinkPC. Pain intensity and side effects during titration of morphine to cancer patients using a fixed schedule dose escalation. Acta Anaesthesiol Scand2000;44:656–664.
KlepstadPKaasaSSkaugeMBorchgrevinkPC. Pain intensity and side effects during titration of morphine to cancer patients using a fixed schedule dose escalation. Acta Anaesthesiol Scand2000;44:656–664.
)| false
KornickCA, Santiago-PalmaJ, KhojainovaN. A safe and effective method for converting cancer patients from intravenous to transdermal fentanyl. Cancer2001;92:3056–3061.
KornickCASantiago-PalmaJKhojainovaN. A safe and effective method for converting cancer patients from intravenous to transdermal fentanyl. Cancer2001;92:3056–3061.
)| false
PortenoyRK, TaylorD, MessinaJ, TremmelL. A randomized, placebo-controlled study of fentanyl buccal tablet for breakthrough pain in opioid-treated patients with cancer. Clin J Pain2006;22:805–811.
PortenoyRKTaylorDMessinaJTremmelL. A randomized, placebo-controlled study of fentanyl buccal tablet for breakthrough pain in opioid-treated patients with cancer. Clin J Pain2006;22:805–811.
)| false
WeinsteinSM, MessinaJ, XieF. Fentanyl buccal tablet for the treatment of breakthrough pain in opioid-tolerant patients with chronic cancer pain: a long-term, open-label safety study. Cancer2009;115:2571–2579.
WeinsteinSMMessinaJXieF. Fentanyl buccal tablet for the treatment of breakthrough pain in opioid-tolerant patients with chronic cancer pain: a long-term, open-label safety study. Cancer2009;115:2571–2579.
)| false
KirchheinerJ, SchmidtH, TzvetkovM. Pharmacokinetics of codeine and its metabolite morphine in ultra-rapid metabolizers due to CYP2D6 duplication. Pharmacogenomics J2007;7:257–265.
KirchheinerJSchmidtHTzvetkovM. Pharmacokinetics of codeine and its metabolite morphine in ultra-rapid metabolizers due to CYP2D6 duplication. Pharmacogenomics J2007;7:257–265.
)| false
WrightAW, MatherLE, SmithMT. Hydromorphone-3-glucuronide: a more potent neuro-excitant than its structural analogue, morphine-3-glucuronide. Life Sci2001;69:409–420.
WrightAWMatherLESmithMT. Hydromorphone-3-glucuronide: a more potent neuro-excitant than its structural analogue, morphine-3-glucuronide. Life Sci2001;69:409–420.
)| false
PortenoyRK, FoleyKM, StulmanJ. Plasma morphine and morphine-6-glucuronide during chronic morphine therapy for cancer pain: plasma profiles, steady-state concentrations and the consequences of renal failure. Pain1991;47:13–19.
PortenoyRKFoleyKMStulmanJ. Plasma morphine and morphine-6-glucuronide during chronic morphine therapy for cancer pain: plasma profiles, steady-state concentrations and the consequences of renal failure. Pain1991;47:13–19.
)| false
AndersenG, JensenNH, ChristrupL. Pain, sedation and morphine metabolism in cancer patients during long-term treatment with sustained-release morphine. Palliat Med2002;16:107–114.
AndersenGJensenNHChristrupL. Pain, sedation and morphine metabolism in cancer patients during long-term treatment with sustained-release morphine. Palliat Med2002;16:107–114.
)| false
DavisMP, VargaJ, DickersonD. Normal-release and controlled-release oxycodone: pharmacokinetics, pharmacodynamics, and controversy. Support Care Cancer2003;11:84–92.
DavisMPVargaJDickersonD. Normal-release and controlled-release oxycodone: pharmacokinetics, pharmacodynamics, and controversy. Support Care Cancer2003;11:84–92.
)| false
AdamZ, PourL, KrejciM. Treatment of AL-amyloidosis— results from one clinic and review of published experience with new agents (bortezomib, thalidomide and lenalidomide) in AL-amyloidosis. Vnitr Lek2010;56:190–209.
AdamZPourLKrejciM. Treatment of AL-amyloidosis— results from one clinic and review of published experience with new agents (bortezomib, thalidomide and lenalidomide) in AL-amyloidosis. Vnitr Lek2010;56:190–209.
)| false
GabrailNY, DvergstenC, AhdiehH. Establishing the dosage equivalency of oxymorphone extended release and oxycodone controlled release in patients with cancer pain: a randomized controlled study. Curr Med Res Opin2004;20:911–918.
GabrailNYDvergstenCAhdiehH. Establishing the dosage equivalency of oxymorphone extended release and oxycodone controlled release in patients with cancer pain: a randomized controlled study. Curr Med Res Opin2004;20:911–918.
)| false
MercadanteS, CasuccioA, FulfaroF. Switching from morphine to methadone to improve analgesia and tolerability in cancer patients: a prospective study. J Clin Oncol2001;19:2898–2904.
MercadanteSCasuccioAFulfaroF. Switching from morphine to methadone to improve analgesia and tolerability in cancer patients: a prospective study. J Clin Oncol2001;19:2898–2904.
)| false
MorylN, Santiago-PalmaJ, KornickC. Pitfalls of opioid rotation: substituting another opioid for methadone in patients with cancer pain. Pain2002;96:325–328.
MorylNSantiago-PalmaJKornickC. Pitfalls of opioid rotation: substituting another opioid for methadone in patients with cancer pain. Pain2002;96:325–328.
)| false
ParsonsHA, de la CruzM, El OstaB. Methadone initiation and rotation in the outpatient setting for patients with cancer pain. Cancer2010;116:520–528.
ParsonsHAde la CruzMEl OstaB. Methadone initiation and rotation in the outpatient setting for patients with cancer pain. Cancer2010;116:520–528.
)| false
KrantzMJ, KutinskyIB, RobertsonAD, MehlerPS. Dose-related effects of methadone on QT prolongation in a series of patients with torsade de pointes. Pharmacotherapy2003;23:802–805.
KrantzMJKutinskyIBRobertsonADMehlerPS. Dose-related effects of methadone on QT prolongation in a series of patients with torsade de pointes. Pharmacotherapy2003;23:802–805.
)| false
ReddyS, HuiD, El OstaB. The effect of oral methadone on the QTc interval in advanced cancer patients: a prospective pilot study. J Palliat Med2010;13:33–38.
ReddySHuiDEl OstaB. The effect of oral methadone on the QTc interval in advanced cancer patients: a prospective pilot study. J Palliat Med2010;13:33–38.
)| false
RodriguezRF, BravoLE, CastroF. Incidence of weak opioids adverse events in the management of cancer pain: a double-blind comparative trial. J Palliat Med2007;10:56–60.
RodriguezRFBravoLECastroF. Incidence of weak opioids adverse events in the management of cancer pain: a double-blind comparative trial. J Palliat Med2007;10:56–60.
)| false
AfilaloM, EtropolskiMS, KuperwasserB. Efficacy and safety of tapentadol extended release compared with oxycodone controlled release for the management of moderate to severe chronic pain related to osteoarthritis of the knee: a randomized, double-blind, placebo- and active-controlled phase III study. Clin Drug Investig2010;30:489–505.
AfilaloMEtropolskiMSKuperwasserB. Efficacy and safety of tapentadol extended release compared with oxycodone controlled release for the management of moderate to severe chronic pain related to osteoarthritis of the knee: a randomized, double-blind, placebo- and active-controlled phase III study. Clin Drug Investig2010;30:489–505.
)| false
BuynakR, ShapiroDY, OkamotoA. Efficacy and safety of tapentadol extended release for the management of chronic low back pain: results of a prospective, randomized, double-blind, placebo- and active-controlled phase III study. Expert Opin Pharmacother2010;11:1787–1804.
BuynakRShapiroDYOkamotoA. Efficacy and safety of tapentadol extended release for the management of chronic low back pain: results of a prospective, randomized, double-blind, placebo- and active-controlled phase III study. Expert Opin Pharmacother2010;11:1787–1804.
)| false
SchwartzS, EtropolskiM, ShapiroDY. Safety and efficacy of tapentadol ER in patients with painful diabetic peripheral neuropathy: results of a randomized-withdrawal, placebo-controlled trial. Curr Med Res Opin2011;27:151–162.
SchwartzSEtropolskiMShapiroDY. Safety and efficacy of tapentadol ER in patients with painful diabetic peripheral neuropathy: results of a randomized-withdrawal, placebo-controlled trial. Curr Med Res Opin2011;27:151–162.)| false
PergolizziJVJr., MercadanteS, EchaburuAV. The role of transdermal buprenorphine in the treatment of cancer pain: an expert panel consensus. Curr Med Res Opin2009;25:1517–1528.
PergolizziJVJr.MercadanteSEchaburuAV. The role of transdermal buprenorphine in the treatment of cancer pain: an expert panel consensus. Curr Med Res Opin2009;25:1517–1528.
)| false
HardyJ, QuinnS, FazekasB. Randomized, double-blind, placebo-controlled study to assess the efficacy and toxicity of subcutaneous ketamine in the management of cancer pain. J Clin Oncol2012;30:3611–3617.
HardyJQuinnSFazekasB. Randomized, double-blind, placebo-controlled study to assess the efficacy and toxicity of subcutaneous ketamine in the management of cancer pain. J Clin Oncol2012;30:3611–3617.
)| false
McNicolE, Horowicz-MehlerN, FiskRA. Management of opioid side effects in cancer-related and chronic noncancer pain: a systematic review. J Pain2003;4:231–256.
McNicolEHorowicz-MehlerNFiskRA. Management of opioid side effects in cancer-related and chronic noncancer pain: a systematic review. J Pain2003;4:231–256.
)| false
BoettgerS, BreitbartW. Atypical antipsychotics in the management of delirium: a review of the empirical literature. Palliat Support Care2005;3:227–237.
BoettgerSBreitbartW. Atypical antipsychotics in the management of delirium: a review of the empirical literature. Palliat Support Care2005;3:227–237.
)| false
BreitbartW, MarottaR, PlattMM. A double-blind trial of haloperidol, chlorpromazine, and lorazepam in the treatment of delirium in hospitalized AIDS patients. Am J Psychiatry1996;153:231–237.
BreitbartWMarottaRPlattMM. A double-blind trial of haloperidol, chlorpromazine, and lorazepam in the treatment of delirium in hospitalized AIDS patients. Am J Psychiatry1996;153:231–237.
)| false
BrueraE, BelzileM, NeumannC. A double-blind, crossover study of controlled-release metoclopramide and placebo for the chronic nausea and dyspepsia of advanced cancer. J Pain Symptom Manage2000;19:427–435.
BrueraEBelzileMNeumannC. A double-blind, crossover study of controlled-release metoclopramide and placebo for the chronic nausea and dyspepsia of advanced cancer. J Pain Symptom Manage2000;19:427–435.
)| false
MarinellaMA. Acute colonic pseudo-obstruction complicated by cecal perforation in a patient with Parkinson’s disease. South Med J1997;90:1023–1026.
MarinellaMA. Acute colonic pseudo-obstruction complicated by cecal perforation in a patient with Parkinson’s disease. South Med J1997;90:1023–1026.
)| false
TarcatuD, TamasdanC, MorylN, ObbensE. Are we still scratching the surface? A case of intractable pruritus following systemic opioid analgesia. J Opioid Manag2007;3:167–170.
TarcatuDTamasdanCMorylNObbensE. Are we still scratching the surface? A case of intractable pruritus following systemic opioid analgesia. J Opioid Manag2007;3:167–170.
)| false
HawleyPH, ByeonJJ. A comparison of sennosides-based bowel protocols with and without docusate in hospitalized patients with cancer. J Palliat Med2008;11:575–581.
HawleyPHByeonJJ. A comparison of sennosides-based bowel protocols with and without docusate in hospitalized patients with cancer. J Palliat Med2008;11:575–581.
)| false
MichnaE, BlonskyER, SchulmanS. Subcutaneous methylnaltrexone for treatment of opioid-induced constipation in patients with chronic, nonmalignant pain: a randomized controlled study. J Pain2011;12:554–562.
MichnaEBlonskyERSchulmanS. Subcutaneous methylnaltrexone for treatment of opioid-induced constipation in patients with chronic, nonmalignant pain: a randomized controlled study. J Pain2011;12:554–562.
)| false
PortenoyRK, ThomasJ, Moehl BoatwrightML. Subcutaneous methylnaltrexone for the treatment of opioid-induced constipation in patients with advanced illness: a double-blind, randomized, parallel group, dose-ranging study. J Pain Symptom Manage2008;35:458–468.
PortenoyRKThomasJMoehl BoatwrightML. Subcutaneous methylnaltrexone for the treatment of opioid-induced constipation in patients with advanced illness: a double-blind, randomized, parallel group, dose-ranging study. J Pain Symptom Manage2008;35:458–468.
)| false
Sanz RubialesA, del Valle RiveroML. Methylnaltrexone for opioid-induced constipation in advanced illness. N Engl J Med2008;359:1070–1071; author reply 1071.
Sanz RubialesAdel Valle RiveroML. Methylnaltrexone for opioid-induced constipation in advanced illness. N Engl J Med2008;359:1070–1071; author reply 1071.
)| false
BrueraE, SeifertL, WatanabeS. Chronic nausea in advanced cancer patients: a retrospective assessment of a metoclopramide-based antiemetic regimen. J Pain Symptom Manage1996;11:147–153.
BrueraESeifertLWatanabeS. Chronic nausea in advanced cancer patients: a retrospective assessment of a metoclopramide-based antiemetic regimen. J Pain Symptom Manage1996;11:147–153.
)| false
GagnonP, AllardP, MasseB, DeSerresM. Delirium in terminal cancer: a prospective study using daily screening, early diagnosis, and continuous monitoring. J Pain Symptom Manage2000;19:412–426.
GagnonPAllardPMasseBDeSerresM. Delirium in terminal cancer: a prospective study using daily screening, early diagnosis, and continuous monitoring. J Pain Symptom Manage2000;19:412–426.
)| false
BrueraE, MacmillanK, HansonJ, MacDonaldRN. The cognitive effects of the administration of narcotic analgesics in patients with cancer pain. Pain1989;39:13–16.
BrueraEMacmillanKHansonJMacDonaldRN. The cognitive effects of the administration of narcotic analgesics in patients with cancer pain. Pain1989;39:13–16.
)| false
NCHS Data Brief. Centers for Disease Control and Prevention Web site. Available at: http://www.cdc.gov/nchs/data/databriefs/db81.htm. Accessed July 17, 2013.
NCHS Data Brief. Centers for Disease Control and Prevention Web site. Available at: http://www.cdc.gov/nchs/data/databriefs/db81.htm. Accessed July 17, 2013.
)| false
Risk Evaluation and Mitigation Strategy (REMS) for Extended-Release and Long-Acting Opioids. U.S. Food and Drug Administration Web site. Available at: http://www.fda.gov/drugs/drugsafety/informationbydrugclass/ucm163647.htm. Accessed July 17, 2013.
Risk Evaluation and Mitigation Strategy (REMS) for Extended-Release and Long-Acting Opioids. U.S. Food and Drug Administration Web site. Available at: http://www.fda.gov/drugs/drugsafety/informationbydrugclass/ucm163647.htm. Accessed July 17, 2013.
)| false
Approved Risk Evaluation and Mitigation Strategies (REMS). U.S. Food and Drug Administration Web site. Available at: http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm111350.htm. Accessed July 17, 2013.
Approved Risk Evaluation and Mitigation Strategies (REMS). U.S. Food and Drug Administration Web site. Available at: http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm111350.htm. Accessed July 17, 2013.
)| false
NCCN Resource Tool: Risk Evaluation & Mitigation Strategies (REMS). National Comprehensive Cancer Network Web site. Available at: http://www.nccn.org/rems/default.asp. Accessed July 17, 2013.
NCCN Resource Tool: Risk Evaluation & Mitigation Strategies (REMS). National Comprehensive Cancer Network Web site. Available at: http://www.nccn.org/rems/default.asp. Accessed July 17, 2013.
)| false
AubertR, StanekEJ, YaoJ. Risk of breast cancer recurrence in women initiating tamoxifen with CYP2D6 inhibitors [abstract]. J Clin Oncol2009;27(Suppl):Abstract CRA508
AubertRStanekEJYaoJ. Risk of breast cancer recurrence in women initiating tamoxifen with CYP2D6 inhibitors [abstract]. J Clin Oncol2009;27(Suppl):Abstract CRA508)| false
DezentjeV, Van BlijderveenNJ, GelderblomH. Concomitant CYP2D6 inhibitor use and tamoxifen adherence in early-stage breast cancer: a pharmacoepidemiologic study [abstract]. J Clin Oncol2009;27(Suppl):Abstract CRA509.
DezentjeVVan BlijderveenNJGelderblomH. Concomitant CYP2D6 inhibitor use and tamoxifen adherence in early-stage breast cancer: a pharmacoepidemiologic study [abstract]. J Clin Oncol2009;27(Suppl):Abstract CRA509.
)| false
JinY, DestaZ, StearnsV. CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. J Natl Cancer Inst2005;97:30–39.
JinYDestaZStearnsV. CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. J Natl Cancer Inst2005;97:30–39.
)| false
Johannessen LandmarkC. Antiepileptic drugs in non-epilepsy disorders: relations between mechanisms of action and clinical efficacy. CNS Drugs2008;22:27–47.
Johannessen LandmarkC. Antiepileptic drugs in non-epilepsy disorders: relations between mechanisms of action and clinical efficacy. CNS Drugs2008;22:27–47.
)| false
BaronR, BrunnmullerU, BrasserM. Efficacy and safety of pregabalin in patients with diabetic peripheral neuropathy or postherpetic neuralgia: open-label, non-comparative, flexible-dose study. Eur J Pain2008;12:850–858.
BaronRBrunnmullerUBrasserM. Efficacy and safety of pregabalin in patients with diabetic peripheral neuropathy or postherpetic neuralgia: open-label, non-comparative, flexible-dose study. Eur J Pain2008;12:850–858.
)| false
Bar AdV, WeinsteinG, DuttaPR. Gabapentin for the treatment of pain syndrome related to radiation-induced mucositis in patients with head and neck cancer treated with concurrent chemoradiotherapy. Cancer2010;116:4206–4213.
Bar AdVWeinsteinGDuttaPR. Gabapentin for the treatment of pain syndrome related to radiation-induced mucositis in patients with head and neck cancer treated with concurrent chemoradiotherapy. Cancer2010;116:4206–4213.
)| false
BennettMI. Effectiveness of antiepileptic or antidepressant drugs when added to opioids for cancer pain: systematic review. Palliat Med2011;25:553–559.
BennettMI. Effectiveness of antiepileptic or antidepressant drugs when added to opioids for cancer pain: systematic review. Palliat Med2011;25:553–559.
)| false
GammaitoniAR, AlvarezNA, GalerBS. Safety and tolerability of the lidocaine patch 5%, a targeted peripheral analgesic: a review of the literature. J Clin Pharmacol2003;43:111–117.
GammaitoniARAlvarezNAGalerBS. Safety and tolerability of the lidocaine patch 5%, a targeted peripheral analgesic: a review of the literature. J Clin Pharmacol2003;43:111–117.
)| false
StocklerM, VardyJ, PillaiA, WarrD. Acetaminophen (paracetamol) improves pain and well-being in people with advanced cancer already receiving a strong opioid regimen: a randomized, double-blind, placebo-controlled cross-over trial. J Clin Oncol2004;22:3389–3394.
StocklerMVardyJPillaiAWarrD. Acetaminophen (paracetamol) improves pain and well-being in people with advanced cancer already receiving a strong opioid regimen: a randomized, double-blind, placebo-controlled cross-over trial. J Clin Oncol2004;22:3389–3394.
)| false
BodyJJ, DielIJ, LichinitzerM. Oral ibandronate reduces the risk of skeletal complications in breast cancer patients with metastatic bone disease: results from two randomised, placebo-controlled phase III studies. Br J Cancer2004;90:1133–1137.
BodyJJDielIJLichinitzerM. Oral ibandronate reduces the risk of skeletal complications in breast cancer patients with metastatic bone disease: results from two randomised, placebo-controlled phase III studies. Br J Cancer2004;90:1133–1137.
)| false
BodyJJ, DielIJ, BellR. Oral ibandronate improves bone pain and preserves quality of life in patients with skeletal metastases due to breast cancer. Pain2004;111:306–312.
BodyJJDielIJBellR. Oral ibandronate improves bone pain and preserves quality of life in patients with skeletal metastases due to breast cancer. Pain2004;111:306–312.
)| false
CleelandCS, BodyJJ, StopeckA. Pain outcomes in patients with advanced breast cancer and bone metastases: results from a randomized, double-blind study of denosumab and zoledronic acid. Cancer2013;119:832–838.
CleelandCSBodyJJStopeckA. Pain outcomes in patients with advanced breast cancer and bone metastases: results from a randomized, double-blind study of denosumab and zoledronic acid. Cancer2013;119:832–838.
)| false
RosenLS, GordonD, KaminskiM. Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial. Cancer J2001;7:377–387.
RosenLSGordonDKaminskiM. Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial. Cancer J2001;7:377–387.
)| false
WardleyA, DavidsonN, Barrett-LeeP. Zoledronic acid significantly improves pain scores and quality of life in breast cancer patients with bone metastases: a randomised, crossover study of community vs hospital bisphosphonate administration. Br J Cancer2005;92:1869–1876.
WardleyADavidsonNBarrett-LeeP. Zoledronic acid significantly improves pain scores and quality of life in breast cancer patients with bone metastases: a randomised, crossover study of community vs hospital bisphosphonate administration. Br J Cancer2005;92:1869–1876.
)| false
MalviyaA, GerrandC. Evidence for orthopaedic surgery in the treatment of metastatic bone disease of the extremities: a review article. Palliat Med2012;26:788–796.
MalviyaAGerrandC. Evidence for orthopaedic surgery in the treatment of metastatic bone disease of the extremities: a review article. Palliat Med2012;26:788–796.
)| false
RaphaelJ, HesterJ, AhmedzaiS. Cancer pain: part 2: physical, interventional and complimentary therapies; management in the community; acute, treatment-related and complex cancer pain: a perspective from the British Pain Society endorsed by the UK Association of Palliative Medicine and the Royal College of General Practitioners. Pain Med2010;11:872–896.
RaphaelJHesterJAhmedzaiS. Cancer pain: part 2: physical, interventional and complimentary therapies; management in the community; acute, treatment-related and complex cancer pain: a perspective from the British Pain Society endorsed by the UK Association of Palliative Medicine and the Royal College of General Practitioners. Pain Med2010;11:872–896.
)| false
PfisterDG, CassilethBR, DengGE. Acupuncture for pain and dysfunction after neck dissection: results of a randomized controlled trial. J Clin Oncol2010;28:2565–2570.
PfisterDGCassilethBRDengGE. Acupuncture for pain and dysfunction after neck dissection: results of a randomized controlled trial. J Clin Oncol2010;28:2565–2570.
)| false
HuangST, GoodM, ZauszniewskiJA. The effectiveness of music in relieving pain in cancer patients: a randomized controlled trial. Int J Nurs Stud2010;47:1354–1362.
HuangSTGoodMZauszniewskiJA. The effectiveness of music in relieving pain in cancer patients: a randomized controlled trial. Int J Nurs Stud2010;47:1354–1362.
)| false
KwekkeboomKL, CherwinCH, LeeJW, WantaB. Mind-body treatments for the pain-fatigue-sleep disturbance symptom cluster in persons with cancer. J Pain Symptom Manage2010;39:126–138.
KwekkeboomKLCherwinCHLeeJWWantaB. Mind-body treatments for the pain-fatigue-sleep disturbance symptom cluster in persons with cancer. J Pain Symptom Manage2010;39:126–138.
)| false
CassilethBR, KeefeFJ. Integrative and behavioral approaches to the treatment of cancer-related neuropathic pain. Oncologist2010;15(Suppl 2):19–23.
CassilethBRKeefeFJ. Integrative and behavioral approaches to the treatment of cancer-related neuropathic pain. Oncologist2010;15(Suppl 2):19–23.
)| false
MontgomeryGH, WeltzCR, SeltzM, BovbjergDH. Brief presurgery hypnosis reduces distress and pain in excisional breast biopsy patients. Int J Clin Exp Hypn2002;50:17–32.
MontgomeryGHWeltzCRSeltzMBovbjergDH. Brief presurgery hypnosis reduces distress and pain in excisional breast biopsy patients. Int J Clin Exp Hypn2002;50:17–32.
)| false
PuchalskiC, FerrellB, ViraniR. Improving the quality of spiritual care as a dimension of palliative care: the report of the Consensus Conference. J Palliat Med2009;12:885–904.
PuchalskiCFerrellBViraniR. Improving the quality of spiritual care as a dimension of palliative care: the report of the Consensus Conference. J Palliat Med2009;12:885–904.
)| false
BennettMI, BagnallAM, Jose ClossS. How effective are patient-based educational interventions in the management of cancer pain? Systematic review and meta-analysis. Pain2009;143:192–199.
BennettMIBagnallAMJose ClossS. How effective are patient-based educational interventions in the management of cancer pain? Systematic review and meta-analysis. Pain2009;143:192–199.
)| false
EidelmanA, WhiteT, SwarmRA. Interventional therapies for cancer pain management: important adjuvants to systemic analgesics. J Natl Compr Canc Netw2007;5:753–760.
EidelmanAWhiteTSwarmRA. Interventional therapies for cancer pain management: important adjuvants to systemic analgesics. J Natl Compr Canc Netw2007;5:753–760.
)| false
WongGY, SchroederDR, CarnsPE. Effect of neurolytic celiac plexus block on pain relief, quality of life, and survival in patients with unresectable pancreatic cancer: a randomized controlled trial. JAMA2004;291:1092–1099.
WongGYSchroederDRCarnsPE. Effect of neurolytic celiac plexus block on pain relief, quality of life, and survival in patients with unresectable pancreatic cancer: a randomized controlled trial. JAMA2004;291:1092–1099.
)| false
ZhangCL, ZhangTJ, GuoYN. Effect of neurolytic celiac plexus block guided by computerized tomography on pancreatic cancer pain. Dig Dis Sci2008;53:856–860.
ZhangCLZhangTJGuoYN. Effect of neurolytic celiac plexus block guided by computerized tomography on pancreatic cancer pain. Dig Dis Sci2008;53:856–860.
)| false
SmithTJ, StaatsPS, DeerT. Randomized clinical trial of an implantable drug delivery system compared with comprehensive medical management for refractory cancer pain: impact on pain, drug-related toxicity, and survival. J Clin Oncol2002;20:4040–4049.
SmithTJStaatsPSDeerT. Randomized clinical trial of an implantable drug delivery system compared with comprehensive medical management for refractory cancer pain: impact on pain, drug-related toxicity, and survival. J Clin Oncol2002;20:4040–4049.
)| false
DeerTR, PragerJ, LevyR. Polyanalgesic Consensus Conference 2012: recommendations for the management of pain by intrathecal (intraspinal) drug delivery: report of an interdisciplinary expert panel. Neuromodulation2012;15:436–464; discussion 464-436.
DeerTRPragerJLevyR. Polyanalgesic Consensus Conference 2012: recommendations for the management of pain by intrathecal (intraspinal) drug delivery: report of an interdisciplinary expert panel. Neuromodulation2012;15:436–464; discussion 464-436.
)| false
BerensonJ, PflugmacherR, JarzemP. Balloon kyphoplasty versus non-surgical fracture management for treatment of painful vertebral body compression fractures in patients with cancer: a multicentre, randomised controlled trial. Lancet Oncol2011;12:225–235.
BerensonJPflugmacherRJarzemP. Balloon kyphoplasty versus non-surgical fracture management for treatment of painful vertebral body compression fractures in patients with cancer: a multicentre, randomised controlled trial. Lancet Oncol2011;12:225–235.
)| false
ElerakyM, PapanastassiouI, SetzerM. Balloon kyphoplasty in the treatment of metastatic tumors of the upper thoracic spine. J Neurosurg Spine2011;14:372–376.
ElerakyMPapanastassiouISetzerM. Balloon kyphoplasty in the treatment of metastatic tumors of the upper thoracic spine. J Neurosurg Spine2011;14:372–376.
)| false
FlaggA2nd, McGreevyK, WilliamsK. Spinal cord stimulation in the treatment of cancer-related pain: “back to the origins”. Curr Pain Headache Rep2012;16:343–349.
FlaggA2ndMcGreevyKWilliamsK. Spinal cord stimulation in the treatment of cancer-related pain: “back to the origins”. Curr Pain Headache Rep2012;16:343–349.
)| false
DupuyDE, LiuD, HartfeilD. Percutaneous radiofrequency ablation of painful osseous metastases: a multicenter American College of Radiology Imaging Network trial. Cancer2010;116:989–997.
DupuyDELiuDHartfeilD. Percutaneous radiofrequency ablation of painful osseous metastases: a multicenter American College of Radiology Imaging Network trial. Cancer2010;116:989–997.
)| false
LutzS, BerkL, ChangE. Palliative radiotherapy for bone metastases: an ASTRO evidence-based guideline. Int J Radiat Oncol Biol Phys2011;79:965–976.
LutzSBerkLChangE. Palliative radiotherapy for bone metastases: an ASTRO evidence-based guideline. Int J Radiat Oncol Biol Phys2011;79:965–976.
)| false
